{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:17:25Z","timestamp":1780503445016,"version":"3.54.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,6]]},"DOI":"10.7759\/cureus.98586","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T18:42:58Z","timestamp":1765046578000},"source":"Crossref","is-referenced-by-count":1,"title":["Pembrolizumab-Induced Secondary Cholangitis: A Case Report"],"prefix":"10.7759","author":[{"given":"Nur Aisyah","family":"Muhd Opandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aqeel","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Answar","family":"Abdulrehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9051362","article-title":"Immune checkpoint inhibitors for lung cancer treatment: a review","volume":"9","author":"Onoi K","year":"2020","unstructured":"Onoi K, Chihara Y, Uchino J, et al.. Immune checkpoint inhibitors for lung cancer treatment: a review. J Clin Med. 2020, 9:1362. 10.3390\/jcm9051362","journal-title":"J Clin Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.70082","article-title":"A pharmacovigilance study of immune checkpoint inhibitor-associated cholangitis: insights from the FDA Adverse Event Reporting System","author":"Tan H","year":"2025","unstructured":"Tan H, Ou X, Chen Y, Lan W, Luo L. A pharmacovigilance study of immune checkpoint inhibitor-associated cholangitis: insights from the FDA Adverse Event Reporting System. Hepatol Res. 2025, 10.1111\/hepr.70082","journal-title":"Hepatol Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000002280","article-title":"Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management","volume":"33","author":"Pi B","year":"2021","unstructured":"Pi B, Wang J, Tong Y, Yang Q, Lv F, Yu Y. Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management. Eur J Gastroenterol Hepatol. 2021, 33:e858-67. 10.1097\/MEG.0000000000002280","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-024-03135-2","article-title":"Clinical features, treatment, and outcome of pembrolizumab induced cholangitis","volume":"397","author":"Fang W","year":"2024","unstructured":"Fang W, Sun W, Fang W, Zhang J, Wang C. Clinical features, treatment, and outcome of pembrolizumab induced cholangitis. Naunyn Schmiedebergs Arch Pharmacol. 2024, 397:7905-12. 10.1007\/s00210-024-03135-2","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyae060","article-title":"Immune-related adverse event-associated sclerosing cholangitis due to immune checkpoint inhibitors: imaging findings and treatments","volume":"54","author":"Okamoto K","year":"2024","unstructured":"Okamoto K, Hijioka S, Nagashio Y, et al.. Immune-related adverse event-associated sclerosing cholangitis due to immune checkpoint inhibitors: imaging findings and treatments. Jpn J Clin Oncol. 2024, 54:887-94. 10.1093\/jjco\/hyae060","journal-title":"Jpn J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2025.01.037","article-title":"Clinical features and pathological findings by liver biopsy in patients with immune-related sclerosing cholangitis induced by immune checkpoint inhibitors","volume":"57","author":"Yasuda T","year":"2025","unstructured":"Yasuda T, Ito T, Ishikawa T, et al.. Clinical features and pathological findings by liver biopsy in patients with immune-related sclerosing cholangitis induced by immune checkpoint inhibitors. Dig Liver Dis. 2025, 57:877-84. 10.1016\/j.dld.2025.01.037","journal-title":"Dig Liver Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v26.i3.353","article-title":"Programmed cell death-1 inhibitor-related sclerosing cholangitis: a systematic review","volume":"26","author":"Onoyama T","year":"2020","unstructured":"Onoyama T, Takeda Y, Yamashita T, et al.. Programmed cell death-1 inhibitor-related sclerosing cholangitis: a systematic review. World J Gastroenterol. 2020, 26:353-65. 10.3748\/wjg.v26.i3.353","journal-title":"World J Gastroenterol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10959-3","article-title":"Clinical benefit of pembrolizumab in treatment of first line non-small cell lung cancer: a systematic review and meta-analysis of clinical characteristics","volume":"23","author":"Liu W","year":"2023","unstructured":"Liu W, Huo G, Chen P. Clinical benefit of pembrolizumab in treatment of first line non-small cell lung cancer: a systematic review and meta-analysis of clinical characteristics. BMC Cancer. 2023, 23:458. 10.1186\/s12885-023-10959-3","journal-title":"BMC Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-22-244","article-title":"Deep learning for predicting immunotherapeutic efficacy in advanced non-small cell lung cancer patients: a retrospective study combining progression-free survival risk and overall survival risk","volume":"11","author":"He BX","year":"2022","unstructured":"He BX, Zhong YF, Zhu YB, et al.. Deep learning for predicting immunotherapeutic efficacy in advanced non-small cell lung cancer patients: a retrospective study combining progression-free survival risk and overall survival risk. Transl Lung Cancer Res. 2022, 11:670-85. 10.21037\/tlcr-22-244","journal-title":"Transl Lung Cancer Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15797","article-title":"Gastrointestinal: Immune-related sclerosing cholangitis with pembrolizumab: imaging and histological features","volume":"37","author":"Suzuki N","year":"2022","unstructured":"Suzuki N, Ikeda Y, Ono M, Ohmori G, Maeda M. Gastrointestinal: Immune-related sclerosing cholangitis with pembrolizumab: imaging and histological features. J Gastroenterol Hepatol. 2022, 37:1652. 10.1111\/jgh.15797","journal-title":"J Gastroenterol Hepatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/433278-pembrolizumab-induced-secondary-cholangitis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T18:42:59Z","timestamp":1765046579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/433278-pembrolizumab-induced-secondary-cholangitis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,6]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.98586","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,6]]}}}